JP2023548303A - 癌を処置する為の医薬組成物及びその使用方法 - Google Patents

癌を処置する為の医薬組成物及びその使用方法 Download PDF

Info

Publication number
JP2023548303A
JP2023548303A JP2023526030A JP2023526030A JP2023548303A JP 2023548303 A JP2023548303 A JP 2023548303A JP 2023526030 A JP2023526030 A JP 2023526030A JP 2023526030 A JP2023526030 A JP 2023526030A JP 2023548303 A JP2023548303 A JP 2023548303A
Authority
JP
Japan
Prior art keywords
effective amount
venetoclax
decitabine
cedazuridine
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548303A5 (enExample
Inventor
ダオ，キム－ヒエン
キール，ハロルド
オガネシアン，アラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of JP2023548303A publication Critical patent/JP2023548303A/ja
Publication of JP2023548303A5 publication Critical patent/JP2023548303A5/ja
Priority to JP2026042423A priority Critical patent/JP2026083415A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023526030A 2020-10-29 2021-10-27 癌を処置する為の医薬組成物及びその使用方法 Pending JP2023548303A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026042423A JP2026083415A (ja) 2020-10-29 2026-03-16 癌を処置する為の医薬組成物及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107010P 2020-10-29 2020-10-29
US63/107,010 2020-10-29
PCT/US2021/056809 WO2022093930A1 (en) 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026042423A Division JP2026083415A (ja) 2020-10-29 2026-03-16 癌を処置する為の医薬組成物及びその使用方法

Publications (2)

Publication Number Publication Date
JP2023548303A true JP2023548303A (ja) 2023-11-16
JP2023548303A5 JP2023548303A5 (enExample) 2024-10-08

Family

ID=81384423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023526030A Pending JP2023548303A (ja) 2020-10-29 2021-10-27 癌を処置する為の医薬組成物及びその使用方法
JP2026042423A Pending JP2026083415A (ja) 2020-10-29 2026-03-16 癌を処置する為の医薬組成物及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026042423A Pending JP2026083415A (ja) 2020-10-29 2026-03-16 癌を処置する為の医薬組成物及びその使用方法

Country Status (10)

Country Link
US (1) US12697347B2 (enExample)
EP (1) EP4237094A4 (enExample)
JP (2) JP2023548303A (enExample)
KR (1) KR20230097034A (enExample)
CN (2) CN122182592A (enExample)
AU (1) AU2021369508B2 (enExample)
CA (1) CA3188316A1 (enExample)
MX (1) MX2023003305A (enExample)
TW (1) TW202227096A (enExample)
WO (1) WO2022093930A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085848A1 (en) * 2018-09-19 2020-03-19 Otsuka Pharmaceutical Co., Ltd. Low dose combination cda substrate drug/cedazuridine with extended administration
WO2020196665A1 (en) * 2019-03-25 2020-10-01 Otsuka Pharmaceutical Co., Ltd. Antitumor composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US9834576B2 (en) 2013-10-29 2017-12-05 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
WO2021113688A1 (en) 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
JP2024521824A (ja) 2021-05-27 2024-06-04 ヴァンダービルト ユニヴァーシティ マクロライド化合物
MX2024003537A (es) 2021-09-21 2024-05-03 Otsuka Pharma Co Ltd Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085848A1 (en) * 2018-09-19 2020-03-19 Otsuka Pharmaceutical Co., Ltd. Low dose combination cda substrate drug/cedazuridine with extended administration
WO2020196665A1 (en) * 2019-03-25 2020-10-01 Otsuka Pharmaceutical Co., Ltd. Antitumor composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD CANCER JOURNAL, vol. 33, no. 12, JPN6025046103, 2019, pages 2795 - 2804, ISSN: 0005728294 *
GUILLERMO GARCIA-MANERO ET AL.: ""Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross ov", BLOOD, vol. Vol.134，Supplement 1, JPN6025011865, 13 November 2019 (2019-11-13), pages 846, ISSN: 0005728293 *
MICHAEL R SAVONA ET AL.: ""An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multi", THE LANCET HAEMATOLOGY, vol. 6, JPN6025011866, April 2019 (2019-04-01), pages 194 - 203, ISSN: 0005775104 *

Also Published As

Publication number Publication date
CN116018145A (zh) 2023-04-25
TW202227096A (zh) 2022-07-16
KR20230097034A (ko) 2023-06-30
CA3188316A1 (en) 2022-05-05
AU2021369508B2 (en) 2026-07-09
US20230405037A1 (en) 2023-12-21
US12697347B2 (en) 2026-08-04
WO2022093930A1 (en) 2022-05-05
JP2026083415A (ja) 2026-05-19
MX2023003305A (es) 2023-04-13
AU2021369508A1 (en) 2023-03-02
CN122182592A (zh) 2026-06-12
EP4237094A4 (en) 2024-07-10
EP4237094A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
KR101892788B1 (ko) 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
JP2026083415A (ja) 癌を処置する為の医薬組成物及びその使用方法
EP4069254B1 (en) Solid oral dosage forms comprising decitabine and cedazuridine
US20250000887A1 (en) Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US20150335609A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CA3232623A1 (en) Methods of treating myelodysplastic syndromes with decitabine and cedazuridine
IL292882A (en) Dosage of Bruton's tyrosine kinase inhibitor
JP2025507219A (ja) がんを処置するためのイバルチノスタット（ｉｖａｌｔｉｎｏｓｔａｔ）の使用
HK40084686A (en) Pharmaceutical compositions and methods of using the same for treating cancer
HK40121574A (en) Combination decitabine and cedazuridine solid oral dosage forms
HK40082478B (en) Solid oral dosage forms comprising decitabine and cedazuridine
HK40082478A (en) Solid oral dosage forms comprising decitabine and cedazuridine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240930

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260120